UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.
Megan H WongVeronica C JonesWai YuLinda D BossermanSayeh M LavasaniNiki PatelMina S SedrakDaphne B StewartJames R WaismanYuan YuanJoanne E MortimerPublished in: Cancer medicine (2024)
This retrospective, real-world analysis suggests potential clinical utility in UGT1A1 testing for patients receiving sacituzumab, but future trials are needed to confirm the association between genotypes and treatment outcomes.